We respond to news of NHS England and Amgen reaching a national agreement to enable early access to Sotorasib for eligible lung cancer patients in England
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
10 Sept 2021
We respond to Macmillan Cancer Support's new research revealing severe nurse shortages are putting cancer patients at risk
Dr Simon Vincent, Director of Research, Support and Influencing at Breast Cancer Now, said:
08 Sept 2021
Breast Cancer Now welcomes NICE approval of abemaciclib with fulvestrant for routine use on the NHS
The National Institute for Health and Care Excellence (NICE) has today announced its decision to approve abemaciclib with fulvestrant for routine use on the NHS, following its time on the Cancer Drugs Fund since April 2019.
12 Aug 2021
We respond to a new study into the use of ErSO to shrink oestrogen receptor positive breast cancer in mice
Dr Kotryna Temcinaite, Senior Research Communications Manager at Breast Cancer Now, said:
22 Jul 2021
We respond to announcement from NHS England of a new Innovative Medicines Fund
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, responded to the announcement from NHS England of a new Innovative Medicines Fund.
21 Jul 2021
We respond to the latest census of clinical oncologists from The Royal College of Radiologists
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, responded to the latest census of clinical oncologists from The Royal College of Radiologists.
14 Jul 2021
We welcome new treatment method for HER2 positive breast cancer for use on Scotland’s NHS
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
12 Jul 2021
We respond to NHS England breast cancer waiting times: May 2021
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
08 Jul 2021
We respond to new research into fertility drugs and breast cancer risk
Dr Kotryna Temcinaite, Senior Research Communications Manager at Breast Cancer Now, said:
21 Jun 2021
We respond to POLQ inhibitors identified as a new class of targeted drugs for cancers with BRCA mutations
Dr Simon Vincent, Director of Research, Support and Influencing at Breast Cancer Now, said:
17 Jun 2021
We respond to new figures from Cancer Research UK showing thousands fewer breast cancer patients started treatment in the last year in England
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
15 Jun 2021
We respond to a new clinical trial into olaparib use for women with high risk HER2 negative primary breast cancer with altered BRCA genes
Dr Simon Vincent, Director of Research, Support and Influencing at Breast Cancer Now, said:
08 Jun 2021